Nitrosamine Impurities in Canadian Drug Products: What Health Canada's Guidance Actually Requires

It started with a single API supplier in China and became one of the most disruptive GMP compliance events in a generation. The 2018 valsartan recall — triggered by NDMA contamination traced to a process change at Zhejiang Huahai Pharmaceuticals — put every health authority on notice simultaneously. Health Canada pulled more than 20 valsartan-containing products from Canadian pharmacies within weeks of the initial notification.

What followed was not a one-time correction. Between 2018 and 2022, over 90 drug products were recalled in Canada due to nitrosamine contamination. Ranitidine. Metformin. Losartan. Irbesartan. By 2020, Health Canada had issued formal guidance requiring all Canadian drug manufacturers — not just those historically linked to contamination — to complete structured nitrosamine risk assessments across their entire product portfolios.

If your organization completed a risk assessment in 2021 and hasn’t revisited it since, or if your assessment focused only on the drug substance, there’s a real GMP compliance gap worth closing before an inspector finds it first.

What Nitrosamines Are and Why Canada GMP Treats Them Differently

Nitrosamines are N-nitroso compounds formed when secondary or tertiary amines react with nitrosating agents. Under certain conditions — in the presence of sodium nitrite, degradation-prone excipients, or residual solvents — they can form in drug substances, drug products, and even in direct-contact packaging materials.

The concern is carcinogenicity. Most nitrosamines of regulatory interest are classified as probable human carcinogens (IARC Group 2A or 2B). Under ICH M7(R1) — which Health Canada has adopted as the Canadian guidance standard for mutagenic impurities — they’re designated as cohort-of-concern compounds. That classification matters practically: the standard Threshold of Toxicological Concern (TTC) of 1.5 μg/day doesn’t apply. Instead, each compound carries its own calculated acceptable intake (AI) limit derived from rodent carcinogenicity studies using a TD50-based approach.

The most common nitrosamines and their Health Canada-aligned AI limits are:

• NDMA (N-nitrosodimethylamine): 96.0 ng/day
• NDEA (N-nitrosodiethylamine): 26.5 ng/day
• NDBA (N-nitrosodibutylamine): 26.5 ng/day
• NMBA (N-nitroso-N-methyl-4-aminobutyric acid): 96.0 ng/day
• NIPEA (N-nitroso-N-isopropylethylamine): 26.5 ng/day

For nitrosamines where genotoxicity is established but compound-specific potency data is limited, Health Canada defaults to a conservative AI of 18 ng/day. This has real analytical consequences: if a risk assessment uncovers a structurally novel nitrosamine, detection limits in the single-digit nanogram-per-gram range are required. Not every contract lab can reliably deliver that sensitivity in complex pharmaceutical matrices.

Health Canada’s Three-Step Risk Assessment Framework

Health Canada’s guidance on nitrosamine impurities — aligned with the EMA’s 2020 guidance and the FDA’s parallel requirements — asks manufacturers to work through three structured steps. Most organizations that receive inspection findings on this topic didn’t skip the process entirely; they executed it incompletely.

Step 1: Theoretical Risk Assessment

This is a desk exercise, but it’s not a checkbox. The goal is to map every plausible source of nitrosamine formation across the product’s entire lifecycle: the drug substance synthesis route, all reagents and solvents used in manufacturing, every excipient in the formulation (particularly those containing secondary amines or capable of acting as nitrosating agents), direct-contact packaging components, and degradation chemistry under the product’s labelled storage conditions.

The most common gap at this stage is scope. Manufacturers often assess the drug substance and miss excipient-drug substance interaction pathways. Sodium lauryl sulfate — a surfactant present in hundreds of solid oral dosage forms — can contribute to nitrosamine formation when combined with certain amine-containing APIs. Magnesium stearate has been implicated in similar pathways. A defensible Step 1 assessment means the team has looked at the complete system, not just the molecule.

Step 2: Confirmatory Analytical Testing

If the theoretical assessment identifies plausible formation pathways — or if the product belongs to a drug class previously implicated in nitrosamine contamination (sartan antihypertensives, ranitidine-class H2 blockers, certain oral antidiabetics) — you move to confirmatory testing. Health Canada does not mandate testing when Step 1 genuinely identifies no formation pathway, but the reality is that most formulations contain at least one theoretical risk worth verifying analytically before an inspector asks for the data.

Analytical approaches Health Canada finds acceptable:

• LC-MS/MS: The primary method for non-volatile nitrosamines, including NMBA, NDIPA, and NMPA. Sensitivity is excellent in most oral solid matrices.
• GC-MS/MS with headspace or thermal desorption: Better suited for volatile compounds like NDMA and NDEA, particularly in liquid and semi-solid formulations.
• LC-HRMS: Used for structural confirmation when an unexpected or novel nitrosamine appears in the chromatogram.

All methods must be validated per ICH Q2(R1) for the intended product matrix. Using a published USP or European Pharmacopoeia method does not exempt you from demonstrating adequate method performance in your specific formulation. That point generates more inspection observations than it should — the method may be well-characterised in a reference matrix and perform poorly in a tablet containing high levels of amine-bearing excipients.

Step 3: Risk Mitigation and Regulatory Filing

If confirmatory testing returns levels above the applicable AI limit — or if a manufacturing change alters the theoretical risk profile — you’re obligated to act. That means implementing changes (process modifications, raw material re-qualification, alternative excipients where feasible) and filing the appropriate regulatory update with Health Canada.

For products already listed on the Canadian Drug Product Database, a Notifiable Change (NC) or Prior Approval Supplement (PAS) may be required depending on the nature of the change. The threshold for which pathway applies isn’t always intuitive. Consulting Health Canada’s Guidance for Industry: Changes to an Existing Drug Submission before you file saves weeks of back-and-forth with the Therapeutic Products Directorate.

What Health Canada GMP Inspectors Are Finding in 2025–2026

Canada GMP inspections have included nitrosamine-specific line items since 2022, and the frequency has increased. Based on published inspection observation trends and Health Canada’s post-inspection communications to industry, the recurring deficiencies fall into a handful of categories.

Incomplete scope of assessment. Assessments that cover the drug substance but not excipients, packaging, or degradation pathways are the most frequently cited gap. Inspectors now specifically request the full theoretical risk assessment documentation — not a summary statement that the exercise was completed.

No reassessment trigger in change control. A nitrosamine risk assessment is not a one-time deliverable. Organizations that completed their initial assessment in 2020 or 2021 and haven’t integrated reassessment into their change control programs are accumulating quiet compliance risk. Any change that touches the API synthesis route, an excipient supplier, direct-contact packaging materials, or storage conditions should automatically trigger a risk assessment review.

Over-reliance on supplier declarations. Health Canada’s GMP guidelines are clear that manufacturers cannot simply rely on supplier Certificates of Analysis for impurity control. If your theoretical assessment identifies a potential nitrosamine formation pathway through a raw material, your supplier qualification program needs to address it — not just accept a CoA statement that the material is compliant. This is a foundational GMP principle applied unevenly in practice.

Missing attestation in new drug submissions. Since 2021, Health Canada has expected all new drug submissions and certain post-approval amendments to include documentation confirming that a nitrosamine risk assessment has been conducted. Submissions that arrive without this documentation are flagged during administrative review — creating delays of 30 to 90 days before the technical review even begins. That’s avoidable.

Building a Program That Holds Up Inspection After Inspection

The organizations that manage nitrosamine compliance most effectively don’t treat it as a one-time audit response. They treat it as a quality system element with defined owners, triggers, and review cycles.

A sustainable program looks like this:

1. A documented SOP that defines the scope, methodology, and decision criteria for nitrosamine risk assessments, tied explicitly to your new product development and change control workflows.
2. Qualified analytical methods on file — developed and validated for your most common formulation types — ready to deploy when a risk pathway is identified, rather than built from scratch under time pressure.
3. A supplier qualification module that specifically addresses nitrosamine risk for amine-containing APIs and excipients with known formation pathways.
4. A defined review cycle: at minimum annually, and immediately following any manufacturing change or Health Canada guidance update that affects your product’s risk profile.

When in-house LC-MS/MS or GC-MS/MS capacity isn’t available, partnering with a qualified contract laboratory is explicitly recognized under gmp guidelines health canada as a valid approach — provided the lab is appropriately qualified under your quality system and the work is governed by a technical quality agreement that defines responsibilities, detection limits, and reporting timelines. Our team works with Canadian manufacturers on both the risk assessment documentation and the analytical testing under accredited, GMP-aligned conditions.

The nitrosamine guidance landscape is still evolving. Health Canada continues to update its drug safety communications as new compounds emerge and as the analytical science matures. Tracking ICH M7 working group updates alongside Health Canada’s own published guidance ensures your program doesn’t fall behind a standard that’s still being written.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Nitrosamine and Genotoxic Impurity Testing in the US — How US-based ISO 17025 laboratories approach LC-MS/MS method development and validation for NDMA, NDEA, and novel nitrosamine compounds.
• ICH M7 Compliance for EU Drug Submissions — How the EMA’s nitrosamine guidance aligns with REACH and European market authorization requirements for pharmaceutical manufacturers.